LEMS Family Association Named Top Five Finalist in 2026 Prix Galien Patient First Award
A meaningful milestone recognizing the power of the LEMS patient community and the impact of collaboration.
The LEMS Family Association is proud to announce that we have been named a Top Five Finalist in the 2026 Prix Galien Patient First Awards, in the Private Sector-Led Initiative category!
This recognition is especially meaningful given the 41 other organizations nominated, many representing well-established organizations and significant industry partnerships. Being selected among the top five finalists is an incredible honor for our small but growing organization.
What Are the Prix Galien Awards?
The Prix Galien is one of the most prestigious recognitions in healthcare and life sciences, often described as the Nobel Prize of the biopharmaceutical industry. The awards recognize outstanding achievements and innovation that advance human health.
The Patient First Awards specifically celebrate initiatives that prioritize the patient experience and demonstrate meaningful collaboration to improve healthcare. The Private Sector-Led Initiative category recognizes efforts that bring together organizations and industry partners to make a difference in the lives of patients.
A Community Making an Impact
Since its founding, the LEMS Family Association has worked to ensure that no one navigating a Lambert-Eaton Myasthenic Syndrome (LEMS) diagnosis feels alone. Our mission is to improve the lives of individuals and families affected by LEMS through education, advocacy, and research.
What began as a vision has grown into a community of nearly 400 patients and caregivers across 47 states and 12 countries. Through patient education programs, peer support opportunities, medical community engagement, and industry partnerships, we continue to create meaningful connections and elevate the voices of those affected by LEMS.
This recognition belongs to the entire LEMS community. It reflects the dedication of our patients and caregivers who share their experiences, the volunteers who give their time, the medical professionals who support our mission, and the partners who believe in the importance of advancing awareness and care for this rare disease.
As a small nonprofit, this recognition reinforces that meaningful impact isn’t measured by the size of an organization, but by the strength of its community and the commitment behind its mission.
We are incredibly grateful to everyone who has helped make this possible. This is a milestone worth celebrating, and we look forward to continuing this work together.